State variations in chronic obstructive pulmonary disease (COPD) outcomes suggest that the condition is more common in large rural areas compared with metropolitan areas, according to the Morbidity and Mortality Weekly Report from CDC.
State variations in chronic obstructive pulmonary disease (COPD) outcomes suggest that the condition is more common in large rural areas compared with metropolitan areas, according to the Morbidity and Mortality Weekly Report from CDC.
The report analyzed 2015 data from the Behavioral Risk Factor Surveillance System, Medicare hospital records, and death certificate data from the National Vital Statistics System, and identified 15.5 million adults who received a COPD diagnosis with approximately 335,000 Medicare hospitalizations and 150,350 deaths in which COPD was the underlying cause.
The analysis found that COPD prevalence, Medicare hospitalizations, and deaths were “significantly higher” among people in rural areas compared with people in other areas of the country.
Age-adjusted prevalence of COPD diagnosis ranged from 4.7% among populations in large metropolitan centers to 8.2% in rural areas. The analysis also found that 7 states were in the highest quartiles for COPD prevalence, Medicare hospitalizations, and deaths: Alabama, Arkansas, Indiana, Kentucky, Mississippi, Tennessee, and West Virginia. Of those 7 states, Arkansas, Mississippi, and West Virginia were also in the highest quartile for percentage of rural residents.
The researchers speculated that rural populations had a higher risk of COPD because they have a greater proportion with a history of smoking, less access to smoking cessation programs, and higher proportions of uninsured or lower socioeconomic residents. Barriers to care in these areas include cultural perceptions about seeking care, distance to travel for care, a lack of services available, and financial burden. Limited access to services also affects access to early diagnosis, prompt treatment, and management of COPD.
“Healthcare providers and community partners who serve rural residents can help adults with COPD increase access to and participation in healthcare interventions,” the authors concluded. “Federal agencies are promoting collaborative and coordinated efforts to educate the public, providers, patients, and caregivers about COPD and improve the prevention, diagnosis, and treatment of COPD.”
References
Croft JB, Wheaton AG, Liu Y, et al. Urban-rural county and state differences in chronic obstructive pulmonary disease—United States, 2015. MMWR Morb Mortal Wkly Rep. 2018:67(7);205-211. doi: http://dx.doi.org/10.15585/mmwr.mm6707a1.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More